The Eyes Have It: How AI Is Redefining Parkinson's and Challenging a Gold Standard

NEW YORK, NY – June 03, 2026 – For decades, the fight against Parkinson's disease has been hampered by a fundamental problem: the inability to accurately measure its slow, insidious progression. Now, a healthtech firm is challenging the status quo with an AI-powered tool that tracks the disease through subtle eye movements. In a stunning turn that signals a paradigm shift in neurology, the new technology has been validated in a peer-reviewed study led by the very scientists who developed the current gold-standard measurement scale they now find lacking.

The study, published in the leading drug development journal Pharmaceutical Medicine, demonstrates that biomarkers from NeuraLight, a New York and Tel Aviv-based company, can detect disease progression where the established Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) cannot. This breakthrough isn't just a technical achievement; it's a potential turning point for the millions of people living with Parkinson's, offering a clearer path toward the holy grail of a disease-modifying therapy.

A Crisis of Measurement

The grim reality for neurological drug development is a 6% approval rate, less than half that of other therapeutic areas. A primary culprit is the reliance on subjective, inconsistent clinical endpoints. For Parkinson's, the MDS-UPDRS has been the benchmark. The scale involves a clinician observing a patient perform tasks like finger tapping and walking, then assigning a score. While foundational, its weakness is its subjectivity. A score can vary from one doctor to another, from one clinic to the next, and even based on the time of day.

This "rater variability" creates statistical noise that can obscure the subtle signs of a drug's effectiveness or a disease's progression over time. In a field where no therapy has ever been approved to slow Parkinson's, this measurement crisis has been a monumental roadblock. Promising compounds may have been abandoned simply because the tools used to evaluate them weren't sensitive enough to detect their impact.

"No treatment has been approved to slow Parkinson's, partly because measuring progression reliably enough to detect a real drug effect has been one of the field's hardest problems," said Edmund Ben-Ami, Co-Founder and Chief Executive Officer of NeuraLight. The company's recent study, which followed 280 patients across two trials in the US, Europe, and Israel, starkly illustrated this issue. Over the same period, NeuraLight's objective biomarkers showed a clear, statistically significant signal of disease progression, while the MDS-UPDRS scores did not.

The Saccadic Solution: Seeing Progression with New Clarity

NeuraLight’s innovation lies in looking where others haven't—or at least, not with this level of precision. The platform uses AI to analyze oculometrics, or the science of eye movement. It can be deployed on a standard tablet or computer, using the built-in camera to track a person's eyes as they follow targets on the screen in a test that takes about 10 minutes.

The key biomarker highlighted in the study is the Amplitude of Saccadic Hypometria (ASH). Saccades are the rapid, voluntary eye movements we make to shift our gaze from one point to another. In Parkinson's patients, these movements often undershoot their target, a phenomenon known as hypometria. This isn't a random glitch; it's a direct functional readout of the basal ganglia, the deep-brain circuitry that degenerates in Parkinson's and drives its primary motor symptoms.

By precisely quantifying this undershooting, the ASH biomarker provides an objective, numerical measure of this core neurological dysfunction. In the recent study, ASH showed significant deterioration across two independent patient cohorts with a P-value of less than 0.0001, indicating an extremely high level of statistical confidence. Crucially, the results were consistent across all clinical sites, eliminating the rater variability that plagues the MDS-UPDRS. The technology essentially translates a subtle, almost invisible neurological sign into hard, reproducible data.

When Pioneers Endorse Progress

Perhaps the most compelling aspect of this story is who led the research. The study was co-authored and led by Prof. Olivier Rascol and Prof. Christopher G. Goetz—two of the principal developers of the very MDS-UPDRS scale that NeuraLight's technology outperformed. It's a rare and powerful moment in science when the architects of a foundational tool publicly validate its successor.

This endorsement is not just a marketing coup; it represents a commitment to scientific progress over legacy. It acknowledges that while the MDS-UPDRS was a vital step forward, technology has now provided a more powerful lens. Prof. Rascol, who also chairs NeuraLight’s Scientific Advisory Board, noted the practical success of the technology. “NeuraLight’s biomarkers have been successfully incorporated into a number of Parkinson’s drug trials, where they demonstrated the ability to detect subtle changes that are generally undetectable when using clinical gold standards,” he stated.

This willingness of established leaders to embrace disruptive innovation is critical for accelerating medical breakthroughs. "It was a privilege to co-author this work with Prof. Goetz and Prof. Rascol," said Ben-Ami. "Our vision is a future where every CNS trial can detect what's happening to patients, and where therapies that work reach them faster."

Unlocking the Next Generation of Therapies

The implications of this breakthrough extend far beyond academic journals. By providing a more sensitive and reliable endpoint for clinical trials, NeuraLight's platform could dramatically de-risk and accelerate pharmaceutical R&D for Parkinson's. More efficient trials mean lower costs, faster timelines, and a greater likelihood of success.

Pharmaceutical companies are already taking note. NeuraLight has active partnerships to integrate its platform into clinical trials, including with Teitur Trophics for its neuroprotective compound and Kariya Pharmaceuticals for its GLP-1/GIP agonist. These collaborations aim to use the objective biomarkers to quantify a drug's neuroprotective effect with a precision previously unattainable.

NeuraLight is part of a broader wave of innovation in digital biomarkers. Companies like NeuroRPM are using wearable sensors to monitor motor symptoms, while others focus on blood-based tests for proteins like alpha-synuclein. However, NeuraLight's non-invasive, accessible, and highly sensitive approach to measuring a direct functional output of the brain gives it a unique position.

For the millions of patients and their families, this technological shift offers more than just hope; it offers a tangible path forward. More accurate measurement in clinical trials is the first step toward finding drugs that work. In the clinic, it could lead to more personalized treatment, allowing doctors to objectively track a patient's response to medication and adjust care accordingly. By turning a simple webcam into a powerful neurological assessment tool, this technology promises to make brain health more measurable, manageable, and ultimately, treatable.